Bringing Precision To Solid Tumor Targets

Insights From Achilles CEO, Iraj Ali

Achilles Therapeutics is betting that its clonal neoantigen-targeting T cell (cNeT) products, combined with an industrial scale advanced manufacturing capability and predictive bioinformatics platform, will have a transformational impact on patients with solid tumors and metastasized cancer.

Ancient city

Syncona biotech firm Achilles Therapeutics Ltd. was founded in 2016 as a spin off from the Francis Crick Institute and University College London. It was built on the work of thoracic oncologist Charles Swanton, a founder of Achilles Therapeutics and chief clinician at Cancer Research UK (CRUK).

Swanton also leads the CRUK-sponsored TRACERx (TRAcking Cancer Evolution through therapy (Rx)) lung study, a nine-year, multi-million-dollar research project aimed at unraveling the mystery of tumor evolution. The study collects...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from C-Suite Speaks

How Vir Bio CEO Marianne De Backer Is Rebuilding Commercial Momentum

 
• By 

From billion-dollar COVID antibody to a strategic reset, Marianne De Backer is navigating Vir's comeback through pipeline focus and disciplined leadership.

The pre|CISION Approach: How Avacta Is Making Toxic Cancer Drugs Safe And More Effective

 
• By 

Avacta's approach to drug delivery is showing how 'masked' chemotherapy can dramatically improve safety profiles while maintaining or enhancing efficacy where it matters most.

UCB’s Alistair Henry On How AI Is Reshaping Biopharma Talent

 
• By 

Artificial intelligence is shaping many facets of the drug development and commercialization continuum. The need for computational skills within drug R&D is also changing what companies are looking for in young talent that is capable of both bridge biological expertise with computational literacy.

Rising Leaders 2025: Stefan König On The Joy Of Watching Talent Grow

 

While there might be different recipes for success in leadership, continuous learning and wide-ranging experiences have made Stefan König ready to lead Merz Therapeutics as CEO.

More from Leadership

How Vir Bio CEO Marianne De Backer Is Rebuilding Commercial Momentum

 
• By 

From billion-dollar COVID antibody to a strategic reset, Marianne De Backer is navigating Vir's comeback through pipeline focus and disciplined leadership.

Execs On The Move: April 2025

 
• By 

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

AI In Drug Discovery: The Patent Implications

 
• By 

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.